Does the media prefer PTCT or UTHR?

In the previous week, United Therapeutics had 7 more articles in the media than PTC Therapeutics. MarketBeat recorded 18 mentions for United Therapeutics and 11 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.49 beat United Therapeutics' score of 0.43 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral United Therapeutics 5 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, EXEL or PTCT?

Exelixis has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 6.30 $782.57M $3.18 18.56 PTC Therapeutics $1.73B 3.02 $682.64M -$0.58 N/A

Does the media refer more to EXEL or PTCT?

In the previous week, PTC Therapeutics had 2 more articles in the media than Exelixis. MarketBeat recorded 11 mentions for PTC Therapeutics and 9 mentions for Exelixis. Exelixis' average media sentiment score of 0.63 beat PTC Therapeutics' score of 0.49 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PTCT or ASND?

In the previous week, PTC Therapeutics had 9 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 11 mentions for PTC Therapeutics and 2 mentions for Ascendis Pharma A/S. PTC Therapeutics' average media sentiment score of 0.49 beat Ascendis Pharma A/S's score of 0.25 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PTCT or HALO?

In the previous week, Halozyme Therapeutics had 11 more articles in the media than PTC Therapeutics. MarketBeat recorded 22 mentions for Halozyme Therapeutics and 11 mentions for PTC Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.61 beat PTC Therapeutics' score of 0.49 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Halozyme Therapeutics 9 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PTCT or BBIO more profitable?

PTC Therapeutics has a net margin of -3.80% compared to BridgeBio Pharma's net margin of -97.03%. Company Net Margins Return on Equity Return on Assets PTC Therapeutics -3.80% N/A -1.32% BridgeBio Pharma -97.03% N/A -61.19%

Does the media favor PTCT or BBIO?

In the previous week, BridgeBio Pharma had 1 more articles in the media than PTC Therapeutics. MarketBeat recorded 12 mentions for BridgeBio Pharma and 11 mentions for PTC Therapeutics. BridgeBio Pharma's average media sentiment score of 0.49 beat PTC Therapeutics' score of 0.49 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

PTC Therapeutics (PTCT) Competitors

$64.70 +2.14 (+3.42%)

Closing price 04:00 PM Eastern

Extended Trading

$64.68 -0.03 (-0.04%)

As of 07:30 PM Eastern

Compare

PTCT vs. UTHR, EXEL, ASND, HALO, and BBIO

Should you buy PTC Therapeutics stock or one of its competitors? PTC Therapeutics's main competitors and comparable companies include United Therapeutics (UTHR), Exelixis (EXEL), Ascendis Pharma A/S (ASND), Halozyme Therapeutics (HALO), and BridgeBio Pharma (BBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does PTC Therapeutics compare to United Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

94.1% of United Therapeutics shares are owned by institutional investors. 5.3% of PTC Therapeutics shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, United Therapeutics had 7 more articles in the media than PTC Therapeutics. MarketBeat recorded 18 mentions for United Therapeutics and 11 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.49 beat United Therapeutics' score of 0.43 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
United Therapeutics	5 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

PTC Therapeutics currently has a consensus price target of $98.25, suggesting a potential upside of 57.05%. United Therapeutics has a consensus price target of $627.31, suggesting a potential upside of 17.74%. Given PTC Therapeutics' higher possible upside, research analysts clearly believe PTC Therapeutics is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
United Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

PTC Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

United Therapeutics has a net margin of 41.56% compared to PTC Therapeutics' net margin of -3.80%. United Therapeutics' return on equity of 20.18% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	N/A	-1.32%
United Therapeutics	41.56%	20.18%	17.98%

United Therapeutics has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.02	$682.64M	-$0.58	N/A
United Therapeutics	$3.18B	7.18	$1.33B	$27.95	19.06

Summary

United Therapeutics beats PTC Therapeutics on 13 of the 16 factors compared between the two stocks.

How does PTC Therapeutics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Exelixis presently has a consensus price target of $50.36, suggesting a potential downside of 14.68%. PTC Therapeutics has a consensus price target of $98.25, suggesting a potential upside of 57.05%. Given PTC Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe PTC Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

Exelixis has a net margin of 35.33% compared to PTC Therapeutics' net margin of -3.80%. Exelixis' return on equity of 42.17% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
PTC Therapeutics	-3.80%	N/A	-1.32%

Exelixis has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

In the previous week, PTC Therapeutics had 2 more articles in the media than Exelixis. MarketBeat recorded 11 mentions for PTC Therapeutics and 9 mentions for Exelixis. Exelixis' average media sentiment score of 0.63 beat PTC Therapeutics' score of 0.49 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

85.3% of Exelixis shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Comparatively, 5.3% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Exelixis has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.30	$782.57M	$3.18	18.56
PTC Therapeutics	$1.73B	3.02	$682.64M	-$0.58	N/A

Summary

Exelixis beats PTC Therapeutics on 10 of the 16 factors compared between the two stocks.

How does PTC Therapeutics compare to Ascendis Pharma A/S?

PTC Therapeutics (NASDAQ:PTCT) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

PTC Therapeutics presently has a consensus target price of $98.25, indicating a potential upside of 57.05%. Ascendis Pharma A/S has a consensus target price of $310.75, indicating a potential upside of 39.54%. Given PTC Therapeutics' higher probable upside, equities research analysts clearly believe PTC Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00

PTC Therapeutics has higher revenue and earnings than Ascendis Pharma A/S. PTC Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.02	$682.64M	-$0.58	N/A
Ascendis Pharma A/S	$814.57M	17.05	-$258M	$12.89	17.28

Ascendis Pharma A/S has a net margin of 70.99% compared to PTC Therapeutics' net margin of -3.80%. Ascendis Pharma A/S's return on equity of 32.54% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	N/A	-1.32%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

In the previous week, PTC Therapeutics had 9 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 11 mentions for PTC Therapeutics and 2 mentions for Ascendis Pharma A/S. PTC Therapeutics' average media sentiment score of 0.49 beat Ascendis Pharma A/S's score of 0.25 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PTC Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats PTC Therapeutics on 8 of the 14 factors compared between the two stocks.

How does PTC Therapeutics compare to Halozyme Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

In the previous week, Halozyme Therapeutics had 11 more articles in the media than PTC Therapeutics. MarketBeat recorded 22 mentions for Halozyme Therapeutics and 11 mentions for PTC Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.61 beat PTC Therapeutics' score of 0.49 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Halozyme Therapeutics	9 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics has a net margin of 24.86% compared to PTC Therapeutics' net margin of -3.80%. Halozyme Therapeutics' return on equity of 260.98% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	N/A	-1.32%
Halozyme Therapeutics	24.86%	260.98%	23.91%

PTC Therapeutics currently has a consensus target price of $98.25, indicating a potential upside of 57.05%. Halozyme Therapeutics has a consensus target price of $94.00, indicating a potential downside of 14.42%. Given PTC Therapeutics' higher possible upside, equities analysts clearly believe PTC Therapeutics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Halozyme Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

PTC Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

97.8% of Halozyme Therapeutics shares are owned by institutional investors. 5.3% of PTC Therapeutics shares are owned by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

PTC Therapeutics has higher revenue and earnings than Halozyme Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.02	$682.64M	-$0.58	N/A
Halozyme Therapeutics	$1.40B	8.93	$316.89M	$3.35	32.79

Summary

Halozyme Therapeutics beats PTC Therapeutics on 10 of the 16 factors compared between the two stocks.

How does PTC Therapeutics compare to BridgeBio Pharma?

PTC Therapeutics (NASDAQ:PTCT) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

In the previous week, BridgeBio Pharma had 1 more articles in the media than PTC Therapeutics. MarketBeat recorded 12 mentions for BridgeBio Pharma and 11 mentions for PTC Therapeutics. BridgeBio Pharma's average media sentiment score of 0.49 beat PTC Therapeutics' score of 0.49 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	3 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.9% of BridgeBio Pharma shares are owned by institutional investors. 5.3% of PTC Therapeutics shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

PTC Therapeutics presently has a consensus target price of $98.25, suggesting a potential upside of 57.05%. BridgeBio Pharma has a consensus target price of $105.42, suggesting a potential upside of 62.09%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83

PTC Therapeutics has a net margin of -3.80% compared to BridgeBio Pharma's net margin of -97.03%.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	N/A	-1.32%
BridgeBio Pharma	-97.03%	N/A	-61.19%

PTC Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

PTC Therapeutics has higher revenue and earnings than BridgeBio Pharma. PTC Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.02	$682.64M	-$0.58	N/A
BridgeBio Pharma	$502.08M	25.32	-$724.93M	-$3.57	N/A

Summary

BridgeBio Pharma beats PTC Therapeutics on 10 of the 16 factors compared between the two stocks.

Get PTC Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTCT vs. The Competition

Export

Metric	PTC Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.22B	$3.90B	$7.20B	$13.28B
Dividend Yield	N/A	3.65%	2.53%	16.36%
P/E Ratio	-111.55	13.55	274.76	26.18
Price / Sales	3.12	1,283.29	632.15	98.25
Price / Cash	7.13	117.60	76.82	53.72
Price / Book	-25.27	17.17	11.21	6.34
Net Income	$682.64M	-$22.69M	$3.50B	$381.90M
7 Day Performance	1.95%	-1.20%	-0.84%	-1.39%
1 Month Performance	-4.25%	-9.68%	-5.42%	-4.31%
1 Year Performance	-1.98%	10.09%	4.38%	-0.35%

PTC Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTCT PTC Therapeutics	4.0734 of 5 stars	$64.70 +3.4%	$98.25 +51.9%	-3.0%	$5.22B	$1.73B	N/A	991	Analyst Forecast Insider Trade
UTHR United Therapeutics	3.9037 of 5 stars	$485.54 +2.1%	$621.00 +27.9%	+18.7%	$20.39B	$3.18B	17.37	1,400	Analyst Forecast Insider Trade
EXEL Exelixis	3.0905 of 5 stars	$58.37 +0.4%	$50.29 -13.9%	+52.7%	$14.41B	$2.32B	18.36	1,077	Trending News Analyst Forecast Analyst Revision
ASND Ascendis Pharma A/S	4.7897 of 5 stars	$230.05 +2.0%	$310.75 +35.1%	+6.0%	$14.07B	$814.57M	17.85	1,189
HALO Halozyme Therapeutics	3.5021 of 5 stars	$112.89 -0.9%	$91.20 -19.2%	+68.5%	$12.93B	$1.40B	33.70	423	Trending News Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTCT) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PTC Therapeutics (PTCT) Competitors

PTCT vs. UTHR, EXEL, ASND, HALO, and BBIO

How does PTC Therapeutics compare to United Therapeutics?

Summary

How does PTC Therapeutics compare to Exelixis?

Summary

How does PTC Therapeutics compare to Ascendis Pharma A/S?

Summary

How does PTC Therapeutics compare to Halozyme Therapeutics?

Summary

How does PTC Therapeutics compare to BridgeBio Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT vs. The Competition

PTC Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PTC Therapeutics (PTCT) Competitors

PTCT vs. UTHR, EXEL, ASND, HALO, and BBIO

How does PTC Therapeutics compare to United Therapeutics?

Do institutionals and insiders hold more shares of PTCT or UTHR?

Does the media prefer PTCT or UTHR?

Do analysts prefer PTCT or UTHR?

Which has more volatility and risk, PTCT or UTHR?

Is PTCT or UTHR more profitable?

Which has better earnings and valuation, PTCT or UTHR?

Summary

How does PTC Therapeutics compare to Exelixis?

Do analysts rate EXEL or PTCT?

Is EXEL or PTCT more profitable?

Which has more risk & volatility, EXEL or PTCT?

Does the media refer more to EXEL or PTCT?

Do institutionals & insiders hold more shares of EXEL or PTCT?

Which has stronger valuation & earnings, EXEL or PTCT?

Summary

How does PTC Therapeutics compare to Ascendis Pharma A/S?

Do analysts rate PTCT or ASND?

Which has stronger earnings & valuation, PTCT or ASND?

Is PTCT or ASND more profitable?

Does the media refer more to PTCT or ASND?

Which has more volatility & risk, PTCT or ASND?

Summary

How does PTC Therapeutics compare to Halozyme Therapeutics?

Does the media favor PTCT or HALO?

Is PTCT or HALO more profitable?

Do analysts rate PTCT or HALO?

Which has more risk and volatility, PTCT or HALO?

Do insiders & institutionals hold more shares of PTCT or HALO?

Which has stronger earnings and valuation, PTCT or HALO?

Summary

How does PTC Therapeutics compare to BridgeBio Pharma?

Does the media favor PTCT or BBIO?

Do insiders and institutionals hold more shares of PTCT or BBIO?

Do analysts rate PTCT or BBIO?

Is PTCT or BBIO more profitable?

Which has more risk & volatility, PTCT or BBIO?

Which has higher earnings & valuation, PTCT or BBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT vs. The Competition

PTC Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools